Sanofi (SNY) Income Statement Analysis

See more : Epigenomics AG (ECX.DE) Income Statement Analysis – Financial Results

Complete financial analysis of Sanofi (SNY) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Sanofi, a leading company in the Drug Manufacturers – General industry within the Healthcare sector.

You may be interested

Napier Ventures Inc. (NPRVF) Income Statement Analysis – Financial Results
R & B Denims Limited (RNBDENIMS.BO) Income Statement Analysis – Financial Results
MacroWell OMG Digital Entertainment Co., Ltd. (3687.TWO) Income Statement Analysis – Financial Results
Confidence Petroleum India Limited (CONFIPET.BO) Income Statement Analysis – Financial Results
Partner Tech Corp. (3097.TWO) Income Statement Analysis – Financial Results

Sanofi (SNY)

Industry: Drug Manufacturers - General

Sector: Healthcare

Website: https://www.sanofi.com

About Sanofi

Sanofi, together with its subsidiaries, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through three segments: Pharmaceuticals, Vaccines, and Consumer Healthcare. The company provides specialty care products, including human monoclonal antibodies; products for multiple sclerosis, neurology, other inflammatory diseases, immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes; and cardiovascular and established prescription products. It also supplies poliomyelitis, pertussis, and hib pediatric vaccines; and influenza, adult booster, meningitis, and travel and endemic vaccines. In addition, the company offers allergy, cough and cold, pain, liver care, physical and mental wellness, probiotics, digestive, and nutritional products; and other products, such as daily body lotions, anti-itch products, moisturizing and soothing lotions, and body and foot creams, as well as powders for eczema. Further, it has various pharmaceutical products and vaccines in development stage. Sanofi has collaboration agreement with GlaxoSmithKline to develop a recombinant Covid-19 vaccine; and a research collaboration with Stanford University School of Medicine to advance the understanding of immunology and inflammation through open scientific exchange. It also has a collaboration and license option agreement with Prellis Biologics, Inc. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was founded in 1973 and is headquartered in Paris, France.

Metric	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007	2006	2005	2004	2003	2002	2001	2000	1999
Revenue	46.03B	45.39B	39.18B	37.37B	37.63B	35.68B	36.22B	34.70B	34.86B	32.00B	31.29B	35.96B	35.06B	32.04B	30.75B	28.82B	29.25B	29.49B	28.49B	15.03B	8.03B	7.46B	6.49B	5.96B	5.35B
Cost of Revenue	14.24B	13.69B	12.26B	12.16B	11.98B	11.32B	11.45B	10.70B	10.92B	10.23B	10.29B	11.08B	10.90B	8.72B	7.88B	7.34B	7.58B	7.59B	7.56B	3.75B	1.43B	1.38B	1.25B	1.44B	1.49B
Gross Profit	31.80B	31.70B	26.92B	25.21B	25.66B	24.36B	24.77B	24.00B	23.94B	21.77B	21.00B	24.88B	24.16B	23.32B	22.87B	21.48B	21.67B	21.90B	20.93B	11.28B	6.61B	6.08B	5.24B	4.52B	3.86B
Gross Profit Ratio	69.07%	69.83%	68.72%	67.47%	68.18%	68.27%	68.40%	69.16%	68.68%	68.03%	67.10%	69.20%	68.90%	72.79%	74.37%	74.55%	74.08%	74.27%	73.47%	75.05%	82.26%	81.50%	80.69%	75.82%	72.11%
Research & Development	6.73B	6.71B	5.69B	5.53B	6.02B	6.35B	5.57B	5.23B	5.08B	4.67B	4.61B	4.91B	4.81B	4.40B	4.58B	4.58B	4.54B	4.43B	4.04B	7.45B	1.31B	1.22B	1.03B	945.00M	0.00
General & Administrative	0.00	0.00	0.00	0.00	0.00	75.00M	106.00M	106.00M	114.00M	-542.00M	-495.00M	182.00M	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Selling & Marketing	0.00	0.00	0.00	9.39B	9.88B	9.86B	10.06B	9.49B	9.38B	9.11B	8.60B	8.95B	8.54B	7.57B	7.33B	7.17B	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
SG&A	10.77B	10.54B	9.56B	9.39B	9.88B	9.93B	10.16B	9.59B	9.50B	8.57B	8.11B	9.13B	8.54B	7.57B	7.33B	7.17B	7.87B	8.02B	8.24B	4.50B	2.47B	2.43B	2.31B	2.02B	1.89B
Other Expenses	6.45B	2.57B	2.53B	2.40B	2.53B	1.70B	1.66B	1.65B	2.23B	3.02B	3.13B	3.02B	3.62B	3.58B	3.14B	-23.00M	3.20B	3.45B	2.93B	-360.73M	-246.94M	-189.64M	-208.00M	-17.00M	995.00M
Operating Expenses	23.94B	19.81B	17.77B	17.32B	18.43B	17.99B	17.39B	16.48B	16.81B	16.25B	15.84B	17.05B	16.97B	15.55B	15.05B	11.72B	15.61B	15.90B	15.21B	11.59B	3.54B	3.46B	3.13B	2.94B	2.89B
Cost & Expenses	38.16B	-7.29B	30.03B	29.48B	30.41B	-7.73B	-7.42B	-7.18B	-7.44B	-5.64B	-5.86B	-7.29B	27.87B	24.27B	22.93B	19.06B	23.20B	23.49B	22.77B	15.34B	4.96B	4.84B	4.38B	4.39B	4.38B
Interest Income	546.00M	206.00M	40.00M	53.00M	141.00M	164.00M	147.00M	68.00M	178.00M	193.00M	109.00M	93.00M	140.00M	105.00M	24.00M	65.00M	190.00M	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Interest Expense	1.09B	461.00M	368.00M	390.00M	444.00M	495.00M	420.00M	924.00M	559.00M	598.00M	609.00M	751.00M	552.00M	467.00M	324.00M	335.00M	329.00M	1.54B	4.71B	2.53B	0.00	0.00	0.00	0.00	0.00
Depreciation & Amortization	3.78B	3.70B	3.13B	3.27B	3.75B	3.46B	3.15B	2.99B	-2.48B	-2.75B	-3.39B	-3.20B	4.91B	5.44B	5.00B	245.00M	4.48B	6.73B	5.95B	2.52B	117.52M	179.16M	301.00M	241.00M	236.00M
EBITDA	12.00B	14.06B	11.29B	17.51B	7.11B	9.36B	10.28B	10.36B	10.23B	9.87B	9.62B	11.43B	10.64B	11.40B	11.40B	10.48B	10.40B	12.12B	11.67B	2.25B	3.19B	3.00B	2.41B	1.82B	1.21B
EBITDA Ratio	26.06%	30.98%	27.47%	26.13%	26.15%	26.24%	28.38%	29.86%	29.36%	30.84%	30.74%	34.77%	30.35%	35.59%	36.98%	34.73%	35.56%	42.26%	47.01%	14.99%	39.67%	37.49%	37.10%	30.49%	22.56%
Operating Income	7.88B	16.79B	8.13B	8.08B	7.69B	12.43B	12.01B	12.34B	12.71B	12.62B	13.01B	15.70B	5.73B	5.96B	6.37B	9.76B	5.92B	5.73B	7.45B	-262.61M	3.07B	2.62B	2.11B	1.58B	971.00M
Operating Income Ratio	17.11%	37.00%	20.74%	21.63%	20.45%	34.84%	33.15%	35.57%	36.46%	39.45%	41.58%	43.67%	16.35%	18.61%	20.70%	33.88%	20.24%	19.43%	26.13%	-1.75%	38.21%	35.09%	32.46%	26.45%	18.15%
Total Other Income/Expenses	-722.00M	-166.00M	-328.00M	24.00M	-229.00M	228.00M	-188.00M	-720.00M	-403.00M	-458.00M	-459.00M	-1.81B	-542.00M	-362.00M	-300.00M	-232.00M	-139.00M	-981.21M	-2.11B	-588.67M	58.76M	-108.64M	34.00M	-17.00M	-48.00M
Income Before Tax	7.15B	10.49B	7.80B	13.80B	2.82B	4.90B	5.62B	5.81B	5.22B	5.61B	4.52B	6.17B	5.32B	5.60B	6.07B	9.49B	5.78B	4.75B	2.64B	-1.84B	3.13B	2.51B	2.14B	1.56B	0.00
Income Before Tax Ratio	15.54%	23.11%	19.91%	36.94%	7.50%	13.75%	15.50%	16.75%	14.98%	17.52%	14.45%	17.15%	15.17%	17.48%	19.73%	32.94%	19.76%	16.10%	9.27%	-12.25%	38.94%	33.63%	32.98%	26.16%	0.00%
Income Tax Expense	1.60B	2.01B	1.56B	1.81B	139.00M	481.00M	1.72B	1.33B	709.00M	1.21B	726.00M	1.11B	455.00M	1.24B	1.36B	2.76B	687.93M	800.12M	477.04M	818.09M	1.06B	747.13M	842.00M	611.00M	346.00M
Net Income	5.40B	8.37B	6.22B	12.29B	2.81B	4.31B	3.89B	4.71B	4.29B	4.39B	3.72B	4.97B	5.69B	4.36B	5.27B	7.19B	5.27B	4.01B	2.26B	-2.66B	2.07B	1.76B	1.59B	985.00M	625.00M
Net Income Ratio	11.73%	18.44%	15.89%	32.90%	7.46%	12.07%	10.75%	13.57%	12.30%	13.72%	11.88%	13.81%	16.24%	13.60%	17.12%	24.94%	18.02%	13.58%	7.92%	-17.70%	25.80%	23.61%	24.43%	16.52%	11.68%
EPS	4.31	6.69	4.97	9.81	2.33	3.45	3.08	3.42	3.38	3.25	2.75	3.70	4.27	3.34	4.03	2.94	3.91	2.97	1.68	-2.92	2.95	2.42	2.17	1.35	0.85
EPS Diluted	4.30	6.66	4.95	9.76	2.31	3.43	3.07	3.39	3.34	3.21	2.71	3.68	4.26	3.33	4.03	2.94	3.89	2.95	1.67	-2.91	2.95	2.42	2.17	1.35	0.85
Weighted Avg Shares Out	1.25B	1.25B	1.25B	1.25B	1.25B	1.25B	1.27B	1.29B	1.32B	1.32B	1.32B	1.33B	1.32B	1.31B	1.31B	1.31B	1.35B	1.35B	1.34B	910.30M	702.75M	727.69M	731.71M	731.23M	730.78M
Weighted Avg Shares Out (Dil)	1.26B	1.26B	1.26B	1.26B	1.26B	1.26B	1.27B	1.30B	1.32B	1.33B	1.34B	1.33B	1.33B	1.31B	1.31B	1.31B	1.35B	1.36B	1.35B	914.80M	705.12M	729.27M	731.71M	731.23M	730.78M

France considering stake in Sanofi's Opella, minister says

October 15, 2024reuters.com

France is considering taking a stake in Sanofi's Opella arm, said finance minister Antoine Armand, to allay concerns that the French drugmaker's plans to sell a 50% stake in Opella to a U.S. private equity firm could result in job...

Should Value Investors Buy Sanofi (SNY) Stock?

October 14, 2024zacks.com

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong...

French government seeking job guarantees from Sanofi over Doliprane production sites

October 14, 2024reuters.com

The French government is seeking job guarantees from drugmaker Sanofi regarding its Doliprane production sites in the event of a sale of its consumer health branch, Economy Minister Antoine Armand said on Monday.

Sanofi in talks to sell consumer healthcare business that makes Dulcolax

October 11, 2024marketwatch.com

Sanofi on Friday said it's in talks with the private equity firm CD&R to sell just over half of its consumer healthcare business, in a deal that could yield billions of dollars for the French drugmaker.

Sanofi in talks to sell 50% stake in consumer health business to CD&R

October 11, 2024reuters.com

Sanofi has entered into discussions with U.S. private equity firm Clayton Dubilier & Rice to sell a controlling 50% stake in its consumer health business Opella, the French pharmaceutical giant said on Friday.

Press Release: Sanofi in discussions to sell a controlling stake in Opella

October 11, 2024globenewswire.com

Sanofi in discussions to sell a controlling stake in Opella Paris, October 11, 2024 . Sanofi today announces that the company has entered into negotiations with CD&R for the potential sale of a 50% controlling stake in Opella, its consumer...

CD&R nears deal to buy Sanofi's consumer unit for $16 bln, Bloomberg News reports

October 10, 2024reuters.com

Private equity firm Clayton Dubilier & Rice (CD&R) is nearing a deal to acquire Sanofi's consumer health unit for about 15 billion euros ($16.4 billion), Bloomberg News reported on Thursday.

Denali-Sanofi scraps mid-stage study for multiple sclerosis drug

October 10, 2024reuters.com

Drug developer Denali Therapeutics said on Thursday its partner Sanofi has discontinued a mid-stage study testing their experimental drug to treat multiple sclerosis as it failed to meet the main and secondary goals.

Press Release: New Beyfortus data featured at IDWeek reinforce real-world effectiveness against RSV disease and hospitalization in infants

October 9, 2024globenewswire.com

New Beyfortus data featured at IDWeek reinforce real-world effectiveness against RSV disease and hospitalization in infants Paris, October 9, 2024. Sanofi advances its ambition to protect all infants from respiratory syncytial virus (RSV) disease with new Beyfortus (nirsevimab) data to...